Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 62, Issue 1, 2006, Pages 70-76

  Kranz, H ^a   Wagner, T ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Controlled release; Fumaric acid; Matrix tablets; Polyvinylacetate polyvinylpyrrolidone; Weakly basic drug

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; CALCIUM PHOSPHATE; LACTOSE; POVIDONE; STARCH; WATER;

ALKALINITY; ARTICLE; CONTROLLED DRUG RELEASE; DRUG DEGRADATION; DRUG FORMULATION; DRUG RELEASE; DRUG SCREENING; DRUG STABILITY; REPRODUCIBILITY; TABLET COMPRESSION; TABLET FORMULATION; TEMPERATURE DEPENDENCE;

CALCIUM PHOSPHATES; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; LACTOSE; METHYLCELLULOSE; PHARMACEUTIC AIDS; PHENYLUREA COMPOUNDS; PIPERIDINES; POVIDONE; SOLUBILITY; STARCH; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TIME FACTORS;

EID: 28444459242     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2005.07.003     Document Type: Article

References (15)

1. J.G. Bauman, B.O. Buckman, A.F. Ghannam, J.E. Hesselgesser, R. Horuk, I. Islam, M. Liang, K.B. May, S.D. Monahan, M.M. Morissey, H.P. Ng, G.P. Wei, W. Xu, and W. Zheng Piperazine derivatives and their use as anti-inflammatory agents, WO 98/56771 1998
2. A.C. Shah Design of oral sustained release drug delivery systems A. Yacobi E. Halperin-Walega Oral Sustained Release Formulation Design and Evaluation 1988 Pergamon Press New York 35 56
3. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliv. Rev. 50 2001 41 67
4. K. Thoma, and I. Ziegler pH-independent release of fenoldopam from pellets with insoluble film coats Eur. J. Pharm. Biopharm. 46 1998 105 113
5. A.S. Tatavarti, K.A. Mehta, L.L. Augsburger, and S.W. Hoag Influence of methacrylic and acrylic acid polymers on the release performance of weakly basic drugs from sustained release hydrophilic matrices J. Pharm. Sci. 93 2004 2319 2331
6. C. Doherty, and P. York Microenvironmental pH control of drug dissolution Int. J. Pharm. 50 1998 223 232
7. R. Espinoza, E. Hong, and L. Villafuerte Influence of admixed citric acid in the release profile of pelanserin hydrochloride from HPMC matrix tablets Int. J. Pharm. 201 2000 165 173
8. K. Kolter, R. Bodmeier, and A. Dashevsky Kombination von Polyvinylacetat mit wasserunlöslichen, säureunlöslichen oder alkaliunlö slichen Polymeren zur Herstellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher stabilität. Deutsche Offenlegungsschrift DE 102 11 289 A 1 2002
9. A. Dashevsky, K. Kolter, and R. Bodmeier pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat® SR 30 D and the enteric polymer dispersion Kollicoat® MAE 30 DP Eur. J. Pharm. Biopharm. 58 2004 45 49
10. K.E. Gabr Effect of organic acids on the release patterns of weakly basic drugs from inert sustained release matrix tablets Eur. J. Pharm. Biopharm. 38 1992 199 202
11. A. Streubel, J. Siepmann, A. Dashevsky, and R. Bodmeier pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets J. Control. Release 67 2000 101 110
12. H. Kranz, C. Guthmann, T. Wagner, R. Lipp, J. Reinhard, Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug, Eur. J. Pharm. Sci., 26 (2005) 47-53.
13. BASF AG, Technical information for Kollidon SR, Ludwigshafen, Germany, 1999.
14. E. Draganoiu, M. Andheria, and A. Sakr Evaluation of the new polyvinylacetate/povidone excipient for matrix sustained release dosage forms Pharm. Ind. 63 2001 624 629
15. Z.J. Shao, M.I. Farooqi, S. Diaz, A.K. Krishna, and N.A. Muhammad Effects of formulation variables and post compression curing on drug release from a new sustained release matrix material: polyvinylacetate / povidone Pharm. Dev. Tech. 6 2001 247 254